Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses...

Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA

Trastuzumab deruxtecan gives strong anti-tumour activity and durable responses in multiple tumour types ( Dr Funda Meric-Bernstram - MD Anderson Cancer Center, Houston, USA )

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced...

Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Neoadjuvant chemo with mFOLFIRINOX shows survival benefit in locally advanced rectal cancer ( Dr Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

PHERGain trial ID's early breast cancer cases that benefit from dual HER2...

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )

Osimertinib after surgery significantly improves survival in resected EGFR...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Osimertinib after surgery significantly improves survival in resected EGFR-mutated NSCLC ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

ASCO 2023: Breast cancer research highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2023: Breast cancer research highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Ciltacabtagene autoleucel greatly reduces risk of disease progression in...

Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA

$Ciltacabtagene autoleucel greatly reduces risk of disease progression in lenalidomide-refractory MM ( Dr Binod Dhakal - Medical College of Wisconsin, Milwaukee, USA )$

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Effectiveness of a cardiovascular health EHR application for cancer survivors...

Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA

Effectiveness of a cardiovascular health EHR application for cancer survivors in community oncology practice ( Prof Kathryn Weaver - Wake Forest School of Medicine, Winston-Salem, USA )

Sintilimab plus chemo shows promise in high-risk locoregionally-advanced...

Prof Jun Ma - Sun Yat-sen University Cancer Center, Guangzhou, China

Sintilimab plus chemo shows promise in high-risk locoregionally-advanced nasopharyngeal carcinoma ( Prof Jun Ma - Sun Yat-sen University Cancer Center, Guangzhou, China )

ASCO 2023: Head and neck highlights

Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA

ASCO 2023: Head and neck highlights ( Dr Glenn Hanna - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2023: Latest in mRCC

Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald

ASCO 2023: Latest in mRCC ( Dr Javier Puente, Dr Cristina Suárez, Prof Stéphane Oudard, Prof Viktor Grünwald )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

More from ecancer